NASDAQ · Financial Statements
Retension Pharmaceuticals Inc. (RTSN) Revenue, Earnings & Financial Statements
$11.41
NASDAQ: RTSN
Market Cap $42.79M
Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)
Full income statement, balance sheet, and cash flow statement for Retension Pharmaceuticals Inc. (RTSN), plus valuation and return ratios.
Annual financials are not yet available for this stock.
Valuation & Return Ratios
Revenue and earnings of other Medical - Pharmaceuticals stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.